The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
Frontiers in Oncology · 26.01.2023 · 13
DOI: 10.3389/fonc.2023.1034897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 26.01.2023. Verfasst von Yicheng Xiong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR -TKIs) could provide survival benefits for locally advanced EGFR -mutant ( EGFR m) non-small cell lung cancer (NSCLC). However, the role of radical surgery for EGFR -TKI treated stage IIIB EGFR m NSCLC remains controversial. This study attempted to assess the feasibility of neoadjuvant EGFR -TKI followed by radical surgery for stage IIIB EGFR m NSCLC. Patients and Methods Between 2013 and 2020, EGFR m lung adenocarcinoma (LUAD) patients in clinical stage IIIB undergoing neoadjuvant EGFR -TKI followed by surgery (T-S-Arm) and EGFR -TKI alone (T-Arm) were reviewed retrospectively in Shanghai Pulmonary Hospital (SPH). The chi-square test, Student’s t -test or Fisher’s exact test was performed for analysis of baseline characteristics. Progression-free survival (PFS) was estimated using the Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify independent predictors of progression.
Results
A total of 43 patients were divided into T-S-Arm (n = 21) and T-Arm (n = 22). Patients were well-balanced between the two arms. The majority of patients were female (n = 25, 58.1%), non-smokers (n = 35, 81.4%), first-generation of EGFR -TKI treatment (n = 39, 90.7%), and exon 19 deletions (19-DEL) (n = 26, 60.5%). The median diagnostic age was 63.0 years [interquartile range (IQR), 54.0-67.5 years). At the cut-off date with June 30th 2022, median follow-up time was 28 months (IQR, 20-39 months). Neoadjuvant EGFR -TKI treatment followed by radical surgery could significantly improve the median PFS compared with patients underwent EGFR -TKI alone (23.0 months vs 14.5 months, P = 0.002). Multivariate Cox regression analysis demonstrated that radical surgery (T-S-Arm vs. T-Arm, HR: 0.406; 95% CI: 0.207-0.793, P = 0.027) was the only independent predictor for disease progression. The stratified analysis demonstrated patients with N2 disease could benefit from radical surgery (HR, 0.258; 95% CI, 0.107-0.618), especially for patients harboring L858R mutation (HR, 0.188; 95% CI, 0.059-0.604).
Conclusions
For stage IIIB EGFR m NSCLC patients, the prognosis might be improved by neoadjuvant EGFR -TKI followed by radical surgery versus EGFR -TKI alone, especially for those with N2 disease and harboring L858R mutation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- Medical Graduate School, Nanchang University, Nanchang, China.
- Department of Animal Experiment Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Clinical Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Zitieren
APA
Xiong, Y., Bian, D., Huang, Z., Yu, H., Huang, J., Zhang, P., He, W., & Liu, H. (2023). The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1034897
Vancouver
Xiong Y, Bian D, Huang Z, Yu H, Huang J, Zhang P, et al. The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1034897
BibTeX
@article{Xiong2023,
author = {Xiong, Yicheng and Bian, Dongliang and Huang, Zhida and Yu, Huansha and Huang, Jie and Zhang, Peng and He, Wenxin and Liu, Hongcheng},
title = {The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1034897}
}
EUVIMED